Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs. Standard 28 Days, Enabling Patients To Achieve And Maintain Target Medication Levels More Quickly
Indivior的數據顯示，使用每月一次的SUBLOCADE可以快速啓動，顯著改善成癮患者的留存情況，特別是在芬太尼陽性參與者中；研究還在一週後與標準的28天相比，進行了第二次SUBLOCADE注射，使患者能更快地達到和維持目標藥物水平。
- Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.
- Presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference, this study highlights the potential of rapid initiation to transform the treatment of opioid use disorder.
- Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks vs current subcutaneous abdominal injection site, were also presented at CSAM.
- SUBLOCADE has received Priority Review designation from the U.S. Food and Drug Administration (FDA) to expand the label to include rapid initiation one hour after a single transmucosal buprenorphine dose as well as inclusion of alternative injection sites.
- 數據顯示，使用每月一次的SUBLOCADE可以快速啓動，顯著改善成癮患者的留存情況，特別是在芬太尼陽性參與者中。研究還在一週後與標準的28天相比，進行了第二次SUBLOCADE注射，使患者能更快地達到和維持目標藥物水平。
- 在2024年加拿大成癮醫學學會（CSAM）會議上發佈的這項研究，突顯了快速啓動的潛力，可以改變治療成癮的方法。
- 在CSAM上還介紹了支持將SUBLOCADE皮下注射到大腿、上臂和臀部等替代注射部位，與當前的皮下腹部注射部位相比。
- SUBLOCADE已獲得美國食品和藥物管理局（FDA）的優先審查指定，以將標籤擴展到包括在單次粘膜丁派諾注射後一小時進行快速啓動，以及替代注射部位的包括。
RICHMOND, Va., Nov. 19, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) last week shared results from a randomized, open-label sub-study in opioid-dependent participants seeking treatment, (NCT04995029) that demonstrates rapid initiation (RI) with SUBLOCADE (buprenorphine extended-release injection) for the treatment of OUD significantly improves treatment retention compared to standard initiation (SI). RI with SUBLOCADE in a single day may reduce barriers to treatment and improve patient retention especially those who frequently inject opioids or use fentanyl without increasing the risk of precipitated opioid withdrawal (POW) symptoms. The data were presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference in Hamilton, Ontario, Canada.
納斯達克/倫敦證券交易所上市的Indivior PLC在弗吉尼亞州里士滿上週分享了一個隨機、開放標籤的亞組研究成果，研究對象是尋求治療的依賴阿片類物質的參與者（NCT04995029），這項研究表明，使用SUBLOCADE（丁派諾緩釋注射劑）進行成癮治療的快速啓動（RI）顯著改善治療留存率，相比標準啓動（SI）。使用SUBLOCADE進行一日內的快速啓動可能減少治療障礙，改善患者的留存，尤其是那些頻繁注射阿片類藥物或使用芬太尼的患者，而不增加引發阿片類撤退症狀（POW）的風險。這些數據是在加拿大安大略省漢密爾頓舉辦的2024年加拿大成癮醫學協會（CSAM）會議上展示的。
譯文內容由第三人軟體翻譯。
